{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:07:23Z","timestamp":1768208843585,"version":"3.49.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cytotoxic T-lymphocyte antigen-4 (CTLA-4) haploinsufficiency is a T-cell hyperactivation disorder that can manifest with both immunodeficiency and immune dysregulation. Approximately one-third of patients may present mild symptoms and remain stable under supportive care. The remaining patients may develop severe multiorgan autoimmunity requiring lifelong immunosuppressive treatment. Hematopoietic stem cell transplantation (HSCT) is potentially curable for patients with treatment-resistant immune dysregulation. Nevertheless, little experience is reported regarding the management of complications post-HSCT. We present case 1 (CTLA-4 haploinsufficiency) and case 2 (CTLA-4 insufficiency-like phenotype) manifesting with severe autoimmunity including cytopenia and involvement of the central nervous system (CNS), lung, and gut and variable impairment of humoral responses. Both patients underwent HSCT for which the main complications were persistent mixed chimerism, infections, and immune-mediated complications [graft-versus-host disease (GVHD) and nodular lung disease]. Detailed management and outcomes of therapeutic interventions post-HSCT are discussed. Concretely, post-HSCT abatacept and human leukocyte antigen (HLA)-matched sibling donor lymphocyte infusions may be used to increase T-cell donor chimerism with the aim of correcting the immune phenotype of CTLA-4 haploinsufficiency.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1070068","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:56:42Z","timestamp":1672135002000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Challenges in immune reconstitution following hematopoietic stem cell transplantation for CTLA-4 insufficiency-like primary immune regulatory disorders"],"prefix":"10.3389","volume":"13","author":[{"given":"Adriana","family":"Margarit-Soler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0ngela","family":"Dey\u00e0-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Torres","family":"Canizales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Vlagea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Trabazo","family":"Del Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia","family":"Planas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Esteve-Sole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Su\u00e1rez-Lled\u00f3","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Badell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat Rovira","family":"Tarrats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000689","article-title":"Primary immune regulatory disorders: A growing universe of immune dysregulation","volume":"20","author":"Chan","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.026","article-title":"Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency","volume":"142","author":"Cepika","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10875-015-0224-7","article-title":"Spectrum of phenotypes associated with mutations in LRBA","volume":"36","author":"Alkhairy","year":"2016","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02012","article-title":"Increased risk for malignancies in 131 affected CTLA4 mutation carriers","volume":"9","author":"Egg","year":"2018","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.662645","article-title":"Different apples, same tree: Visualizing current biological and clinical insights into CTLA-4 insufficiency and LRBA and DEF6 deficiencies","volume":"9","author":"G\u00e1mez-D\u00edaz","year":"2021","journal-title":"Front Pediatr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.04.005","article-title":"Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes","volume":"44","author":"G\u00e1mez-D\u00edaz","year":"2021","journal-title":"BioMed J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-712612","article-title":"CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency","volume":"128","author":"Lo","year":"2016","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4\u2013insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Sci (1979)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13023-022-02249-1","article-title":"Primary immune regulatory disorders: Undiagnosed needles in the haystack","volume":"17","author":"Flinn","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jaci.2017.04.023","article-title":"Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Seidel","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692219","article-title":"The use of biologic modifiers as a bridge to hematopoietic cell transplantation in primary immune regulatory disorders","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00434","article-title":"Conditioning perspectives for primary immunodeficiency stem cell transplants","volume":"7","author":"Shaw","year":"2019","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12890","article-title":"Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells","volume":"29","author":"Dey\u00e0-Mart\u00ednez","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605187","article-title":"Histology of interstitial lung disease in common variable immune deficiency","volume":"11","author":"Dhalla","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better","volume":"126","author":"Gennery","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00552","article-title":"Hematopoietic stem cell transplantation for combined immunodeficiencies, on behalf of IEWP-EBMT","volume":"7","author":"Neven","year":"2020","journal-title":"Front Pediatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01739-x","article-title":"Curative allogeneic hematopoietic stem cell transplantation following reduced toxicity conditioning in adults with primary immunodeficiency","volume":"57","author":"Mar\u00e7ais","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009","volume":"371","author":"Pai","year":"2014","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00239","article-title":"Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): A primary immune deficiency treatment consortium (PIDTC) survey","volume":"11","author":"Chan","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00539","article-title":"Danger signals and graft-versus-host disease: Current understanding and future perspectives","volume":"7","author":"Toubai","year":"2016","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and other HSCT-related major complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000502263","article-title":"HLA matching in unrelated stem cell transplantation up to date","volume":"46","author":"F\u00fcrst","year":"2019","journal-title":"Transfusion Med Hemotherapy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.055","article-title":"Lifelong immune modulation versus hematopoietic cell therapy for inborn errors of immunity","volume":"9","author":"Cooper","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jaci.2016.01.045","article-title":"Hematopoietic stem cell transplantation for CTLA4 deficiency","volume":"138","author":"Slatter","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01177-2","article-title":"The immune deficiency and dysregulation activity (IDDA2.1 \u2018Kaleidoscope\u2019) score and other clinical measures in inborn errors of immunity","volume":"42","author":"Seidel","year":"2022","journal-title":"J Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32834cd67a","article-title":"Gene therapy for primary immunodeficiency","volume":"23","author":"Booth","year":"2011","journal-title":"Curr Opin Pediatr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.031","article-title":"Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation","volume":"132","author":"Cole","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008187","article-title":"How I use allogeneic HSCT for adults with inborn errors of immunity","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: A prospective multicentre study","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jaip.2017.07.045","article-title":"Allogeneic stem cell transplantation in adolescents and young adults with primary immunodeficiencies","volume":"6","author":"Albert","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12997","article-title":"Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations","volume":"190","author":"Verma","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.03.001","article-title":"Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency","volume":"8","author":"Yang","year":"2021","journal-title":"Genes Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.036","article-title":"Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4","volume":"137","author":"Lee","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"101008","DOI":"10.1016\/j.conctc.2022.101008","article-title":"The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial","volume":"30","author":"Krausz","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/bmt.2008.212","article-title":"Mixed chimerism in SCT: conflict or peaceful coexistence","volume":"42","author":"Liesveld","year":"2008","journal-title":"Bone marrow transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00461","article-title":"Allogeneic hematopoietic stem cell transplantation for congenital immune dysregulatory disorders","volume":"7","author":"Bakhtiar","year":"2019","journal-title":"Front Pediatr"},{"key":"B43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/1744666x.2018.1459189","article-title":"Clinical considerations in the hematopoietic stem cell transplant management of primary immunodeficiencies","volume":"14","author":"Laberko","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00381","article-title":"Long term outcome and immune function after hematopoietic stem cell transplantation for primary immunodeficiency","volume":"7","author":"Gennery","year":"2019","journal-title":"Front Pediatrics Front Media S.A"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-029090","article-title":"Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary t-cell\u2013immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype","volume":"109","author":"Cavazzana-Calvo","year":"2007","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jaci.2017.04.023","article-title":"Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Seidel","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184254","article-title":"PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients","volume":"12","author":"Hossain","year":"2017","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.003","article-title":"Cytotoxic T lymphocyte antigen-4 down-regulates T helper 1 cells by increasing expression of signal transducer and activator of transcription 3 in acute graft-versus-Host disease","volume":"22","author":"Zhu","year":"2016","journal-title":"Biol Blood Marrow Transplantation"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2647-4_12","article-title":"In vitro analysis of CTLA-4-Mediated transendocytosis by regulatory T cells","volume":"2559","author":"Waters","year":"2023","journal-title":"Methods Mol Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1070068\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:56:45Z","timestamp":1672135005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1070068\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2022.1070068"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1070068","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"article-number":"1070068"}}